Table 5.

Other biological functions of MI circulating biomarkers.

Biomarkers		Application value	References
S100	S100A8	Prevents myocardial ischemia and stabilize cardiac function after MI	(14)
	S100B, S100A6, S100P	*Associate with ischemic myocardial injury in ACS * Relate to myocardial infarct size	(129)
	S100B	*Down-regulate cardiac myocyte hypertrophy and apoptosis *Affect myocardial metabolism	(74, 75)
IL	sIL-1R2, IL-1, IL-6	Associated with myocardial remodeling after MI	(64, 65, 100)
H-FABP		*Involved in in-stent restenosis *Evaluate the degree of heart reperfusion after ischemic attack *Predict adverse cardiac events and provide risk evaluation	(57, 58, 60, 92–94)
IGF-1		*Affect atherosclerosis progression * Reduce adverse cardiac remodeling after cardiac I/R injury * Improve ventricular arrhythmia after myocardial infarction combined with HGF	(102, 105, 106)
microRNAs	microRNA-145	Prognosticate cardiac function and the risk of developing HF	(40)
	microRNA-1,microRNA-133, microRNA-208	Diagnose sudden death due to early AMI sensitively	(138)
	microRNA-124	Reduce cardiomyocyte apoptosis following MI	(41)
	microRNA-208b	Reduces post-infarction myocardial fibrosis in	(139)
	microRNA−93	Inhibit cardiac remodeling and HF	(140)
	miR-24-3p	Exert cardioprotective effects in myocardial I/R injury	(141)
VEGF	VEGF-A	Inversely correlated with LVEF after MI at 6-month follow-up	(45)
	VEGF-C	Predict all-cause mortality independently	(113)